Bicara Therapeutics Inc. (BCAX)
NASDAQ: BCAX · Real-Time Price · USD
21.51
-0.87 (-3.89%)
May 13, 2026, 3:17 PM EDT - Market open
Bicara Therapeutics Analyst Ratings
Total Analysts
11
Consensus Rating
Buy
Price Target
$30.27
Upside
+40.73%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Hold Maintains $16 → $18 | Hold | Maintains | $16 → $18 | -16.32% | May 12, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $36 → $37 | Buy | Maintains | $36 → $37 | +72.01% | May 12, 2026 |
| Guggenheim | Guggenheim | Strong Buy Initiates $42 | Strong Buy | Initiates | $42 | +95.26% | May 11, 2026 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $14 → $16 | Hold | Maintains | $14 → $16 | -25.62% | Mar 31, 2026 |
| Wedbush | Wedbush | Buy Reiterates $30 | Buy | Reiterates | $30 | +39.47% | Mar 31, 2026 |
| Wells Fargo | Wells Fargo | Hold Maintains $11 → $16 | Hold | Maintains | $11 → $16 | -25.62% | Mar 31, 2026 |
| Citizens | Citizens | Buy Reiterates $31 | Buy | Reiterates | $31 | +44.12% | Mar 31, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $40 → $42 | Strong Buy | Maintains | $40 → $42 | +95.26% | Mar 31, 2026 |
| B of A Securities | B of A Securities | Strong Buy Initiates $35 | Strong Buy | Initiates | $35 | +62.72% | Mar 25, 2026 |
| Citizens | Citizens | Buy Initiates $31 | Buy | Initiates | $31 | +44.12% | Jan 29, 2026 |
| Wedbush | Wedbush | Buy Reiterates $30 | Buy | Reiterates | $30 | +39.47% | Jan 13, 2026 |
| BTIG | BTIG | Strong Buy Initiates $28 | Strong Buy | Initiates | $28 | +30.17% | Jan 8, 2026 |
| Mizuho | Mizuho | Hold Initiates $18 | Hold | Initiates | $18 | -16.32% | Dec 18, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $8 → $11 | Hold | Maintains | $8 → $11 | -48.86% | Nov 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $41 → $40 | Strong Buy | Maintains | $41 → $40 | +85.96% | Aug 22, 2025 |
| Piper Sandler | Piper Sandler | Buy Initiates $36 | Buy | Initiates | $36 | +67.36% | Aug 19, 2025 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 10 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.